AACR Annual Meeting 2021

DATE

Week 1: April 10-15, 2021
Week 2: May 17-21, 2021

LOCATION

Virtual

Image of tumor for AACR 2021 signifying the oncology research done at Charles River

Even in a pandemic, oncology research powers on for the patients waiting on new therapies. Whether you’re working on cell, gene, biologic, or small molecule therapies, keep your programs moving forward with help from the team behind 83% of 2020’s FDA-approved cancer drugs.

Whether you watch the videos or download them on-demand, you won’t want to miss the content of our scientific poster presentations:

Talk To An Author

Cancer Chemistry

 

Poster #294: In Vitro efficacy studies to support engineered T cell therapies

Presented By Sanne Holt, Charles River

Download the PDF

 

Experimental and Molecular Therapeutics

 

Poster #922: End-to-end discovery to support the development of safe and efficacious engineered cell therapies

Presented By Katherine Vousden, Charles River

Download the PDF

 

Poster #1373: Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro

Presented By Sanne Holt, Charles River

Download the PDF

 

Molecular and Cellular Biology / Genetics

 

Poster #2009: Culturing colorectal cancer cell lines in 3D spheroid cultures drives their cytokine profile towards a pro-inflammatory, tumorigenic and highly metastatic phenotype

Presented By Julia Schüler, Charles River

Download the PDF

 

Tumor Biology

 

Poster #2806: Development of an iRFP713-based orthotopic patient derived brain cancer model to study tumor development in vivo

Presented By Julia Schüler, Charles River

Download the PDF

 

Poster #2999: Establishment and characterization of a panel of prostate cancer patient derived xenografts as an emerging platform for translational research

Presented By Julia Schüler, Charles River

Download the PDF

 

Poster #3184: Falcon-X 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy

Presented by Cypre, in collaboration with Charles River

Download the PDF

 

Poster #2933: Inhibition of FLT3 and AXL by gilteritinib controls systemic tumor growth in luciferase-transduced MV-4-11 acute myeloid leukemia

Presented By Na Li, Charles River

Download the PDF

 

Poster #2995: Zebrafish tumor-derived xenografts established from breast cancer PDX models predict treatment outcome and dissemination risk with superior sensitivity and specificity

Presented by BioReperia, in collaboration with Charles River

Download the PDF

 

Talk To An Author

Cancer Chemistry

ePoster Presentation Available
Poster #294: In vitro efficacy studies to support engineered T cell therapies

Sanne Holt, Charles River

Poster #325: Nascent proteome analysis of tumor cells and their microenvironment in cultured human tumor tissues
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (IKP) in Collaboration with Charles River

Experimental and Molecular Therapeutics

ePoster Presentation Available
Poster #922: End-to-end discovery to support the development of safe and efficacious engineered cell therapies

Katherine Vousden, Charles River

ePoster Presentation Available
Poster #1373: Primary or iPSC-derived cell-based cytotoxicity assays to assess potential safety risks of engineered T cell therapies in vitro

Sanne Holt, Charles River

Immunology

Poster #1649: Mechanistic understanding of HPK1 inhibition on enhanced human T cell activation and tumor immunity in a syngeneic model
Nimbus in Collaboration with Charles River

Poster #1558: Radiation therapy and immune checkpoint inhibitor combinations in the E0771 medullary breast adenocarcinoma
Patrick Fadden, Charles River

Molecular and Cellular Biology / Genetics

ePoster Presentation Available
Poster #2009: Culturing colorectal cancer cell lines in 3D spheroid cultures drives their cytokine profile towards a pro-inflammatory, tumorigenic and highly metastatic phenotype

Julia Schüler, Charles River

Tumor Biology

ePoster Presentation Available
Poster #2806: Development of an iRFP713-based orthotopic patient derived brain cancer model to study tumor development in vivo

Julia Schüler, Charles River

ePoster Presentation Available
Poster #2999: Establishment and characterization of a panel of prostate cancer patient derived xenografts as an emerging platform for translational research

Julia Schüler, Charles River

Poster #2770: Evaluation of tumor growth and baseline leukocyte infiltration in Charles River C57BL/6 and Balb/c mice engrafted with MC38, B16F10, RENCA and EMT6 cells
Christoph Eberle, Charles River

ePoster Presentation Available
Poster #3184: Falcon-X 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy

Cypre in Collaboration with Charles River

ePoster Presentation Available
Poster #2933: Inhibition of FLT3 and AXL by gilteritinib controls systemic tumor growth in luciferase-transduced MV-4-11 acute myeloid leukemia

Na Li, Charles River

ePoster Presentation Available
Poster #2995: Zebrafish tumor-derived xenografts established from breast cancer PDX models predict treatment outcome and dissemination risk with superior sensitivity and specificity

BioReparia in Collaboration with Charles River

 

Talk To An Author

Together with our strategic partners, we’re changing the way cancer therapies are discovered and developed. Explore our posters and scientific resources. From 3D modeling systems and cell therapies to assays that explore the TME, you’ll find innovative tools and platforms that are accelerating research with decision-driving data.

 

Want to talk to our scientists? Request your consult now...

Empower your program with insights from our team: browse our collection oncology research-related webinars, blogs, podcasts and literature.

Webinars

3D 20x confocal image of tumor model

Predict Anticancer Efficacy with a New In Vitro 3D Modeling Platform
Presenters: Julia Schueler, PhD, Research Director, Charles River
Kolin Hribar, PhD, Founder and CEO, Cypre

 

microscopic image of cancer cell

Implantable Microdevices: Changing the Game for In Vivo Pharmacology Studies
Presenters: Julia Schueler, PhD, Research Director, Charles River
Oliver Jonas, PhD, Scientific Founder, Kibur Medical

 

Metastasis of cancerous cell

The Right Tools to Optimize Cell Therapies for Oncology
Presenters: David Harris, PhD, Research Director, Charles River
Sanne Holt, PhD, Group Leader, Charles River
Dominic Clarke, PhD, Global Head of Cell Therapy, HemaCare, A Charles River Company

 

Digital rendering of killing of cancer cells

The Value of Bioinformatics to Assess Novel Immuno-Oncology Therapies
Presenters: Patrick Fadden, PhD, Research Director, Charles River
Dominic Pearce, PhD, Senior Bioinformatics Developer, Fios Genomics

 

Zebrafish swimming in aquarium

A New Translational In Vivo Tool for Oncology Drug Discovery: Zebrafish Tumor Xenograft Model
Presenters: Julia Schüler, DVM, PhD, Research Director, Charles River
Anna Erkstam, PhD, Chief Operating Officer (COO), BioReperia AB
Lasse Jensen, PhD, Chief Technical Officer (CTO) and Co-Founder, BioReperia AB

 

Microscopic image of breast cancer

Emergent Humanized Mouse Models Are Driving Immuno-Oncology Strategy
Presenter: Paula Milinani de Marval, PhD, Associate Research Director, Discovery Services, Charles River

 

Woman donating blood to represent the donors for HemaCare

Ensuring source material consistency and continuity for commercialization of advanced therapies
Presenter: Dominic Clarke of HemaCare, Amy Shaw of Beam Therapeutics, and Christopher Good of Biocair

 

 

Podcast

Tumor Cell.

Sounds of Science

S2, E07: In Vitro 3D Models: A Blueprint for Drug Development
Presenter: Dr. Elizabeth Anderson, PhD, Scientific Director, Oncology, Charles River
Dr. Ian Waddell, PhD, Executive Director, Biology, Charles River

 

 

Blogs & Video Blogs

 

Cells, tumor cell

Better In Vitro Cancer Models for Better Cancer Drugs
Presenters: Dr. Elizabeth Anderson, PhD, Scientific Director, Oncology, Charles River
Julia Schüler, DVM, PhD, Research Director, Charles River

 

Hands holding a leukopak bag

Minimizing Risk from the Start: HemaCare Publication Spotlights Starting Material Logistics
Presenter: Dominic Clarke, PhD, Global Head of Cell Therapy, HemaCare, A Charles River Company

 

 

Tools

 

 

Other Resources